Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females

StatusUnknown
PhasePhase 4
Started

Record status This record was last updated September 19, 2024 (before its estimated March 15, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with psychiatric disorders, including depression, anxiety, and schizophrenia, often require antipsychotic medications for symptom management. However, metabolic changes, especially weight gain, are a common and challenging side effect of many antipsychotics. Aripiprazole, an atypical antipsychotic, has shown promise in mitigating this adverse effect when used in combination with other antipsychotic medications.
Trial Details
NCT Number NCT06590298
Lead Sponsor Universiti Putra Malaysia
Conditions
(from sponsor)		 Psychosis, Metabolic Syndrome, Weight Gain
Related terms Metabolic Syndrome, Psychotic Disorders, Weight Gain
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov